Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
Alexia KiefferMatthieu BeuveletAditya SardesaiRobert MusciSandra MilevJulie RoizJason K H LeePublished in: The Journal of infectious diseases (2022)
An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season. While this reduction is driven by term infants, all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.